Medical progress: Staphylococcus aureus infections

New England Journal of Medicine

Volumn 339, Issue 8, 1998, Pages 520-532

  Lowy, Franklin D ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFAZOLIN; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; L 695256; LEVOFLOXACIN; METICILLIN; MINOCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN G; STAPHYLOCOCCUS TOXIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; DRUG CHOICE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TOXIC SHOCK SYNDROME; CHEMISTRY; DRUG EFFECT; PATHOGENICITY; PHYSIOLOGY; VIRULENCE;

DRUG RESISTANCE, MICROBIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 0032551901     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808203390806     Document Type: Review

References (125)

1. Ogston A. Micrococcus poisoning. J Anat 1882;17:24-58.
2. Classics in infectious diseases: "On abscesses": Alexander Ogston (1844-1929). J Infect Dis 1984;6:122-8.
3. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989;320:1188-96.
4. Sheagren JN. Staphylococcus aureus: the persistent pathogen. N Engl J Med 1984;310:1368-73, 1437-42
5. Wilkinson BJ, Biology. In: Crossley KB, Archer GL, eds. The staphylococci in human disease. New York: Churchill Livingstone, 1997:1-38.
6. Novick RP. The Staphylococcus as a molecular genetic system. In: Novick RP, ed. Molecular biology of the staphylococci. New York: VCH 1990:1-37.
7. Schaberg DR, Zervos MJ. Intergeneric and interspecies gene exchange in gram-positive cocci. Antimicrob Agents Chemother 1986;30:817-22.
8. Kessler CM, Nussbaum E, Tuazon CU. Disseminated intravascular coagulation associated with Staphylococcus aureus septicemia is mediated by peptidoglycan-induced platelet aggregation. J Infect Dis 1991;164:101-7.
9. Lee JC. The prospects for developing a vaccine against Staphylococcus aureus. Trends Microbiol 1996;4:162-6.
10. Foster TJ, McDevitt D. Surface-associated proteins of Staphylococcus aureus: their possible roles in virulence. FEMS Microbiol Lett 1994;118: 199-205.
11. Patti JM, Allen BL, McGavin MJ, Höök M. MSCRAMM-mediated adherence of microorganisms to host tissues. Ann Rev Microbiol 1994;48: 585-617.
12. Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991;55:733-51.
13. Walev I, Reske K, Palmer M, Valeva A, Bhakdi S. Potassium-inhibited processing of IL-1β in human monocytes. EMBO J 1995;14:1607-14.
14. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990;248:705-11. [Erratum, Science 1990;248:1066.]
15. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ. Lack of complete correlation between T-cell-stimulatory activities of staphylococcal enterotoxins. Infect Immun 1993;61:3175-83.
16. Cribier B, Prevost G, Couppie P, Finck-Barbancon V, Grosshans E, Piemont Y. Staphylococcus aureus leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992;185:175-80.
17. Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P. Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol 1988;170:4365-72.
18. Cheung AL, Koomey JM, Butler CA, Projan SJ, Fischetti VA. Regulation of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from agr. Proc Natl Acad Sci USA 1992;89:6462-6.
19. Ji G, Beavis RC, Novick RP. Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc Natl Acad Sci U S A 1995;92:12055-9.
20. - mutant of Staphylococcus aureus in the rabbit model of endocarditis. J Clin Invest 1994;94:1815-22.
21. Noble WC, Valkenburg HA, Wolters CHL. Carriage of Staphylococcus aureus in random samples of a normal population. J Hyg (Lond) 1967;65: 567-73.
22. Casewell MW, Hill RLR. The carrier state: methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1986;18:Suppl A:1-12.
23. Sanford MD, Widmer AF, Bale MJ, Jones RN, Wenzel RP. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Intect Dis 1994;19:1123-8.
24. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection J Hosp Infect 1995;31:13-24.
25. Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients: an increased carrier rate. JAMA 1975;231:1272.
26. Tuazon CU, Sheagren JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974;129:725-7.
27. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: efficacy of antibiotic prophylaxis N Engl J Med 1986;315:91-6.
28. Weinstein HJ. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med 1959;260:1303-8.
29. Kluytmans JAJW, Mouton JW, Ijzerman EPF, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995;171:216-9.
30. Weinke T, Schiller R, Fehrenbach FJ, Pohle HD. Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1992;11:985-9.
31. Waldvogel FA. Staphylococcus aureus (including toxic shock syndrome). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. Vol. 2. New York: Churchill Livingstone, 1995:1754-77.
32. Sheretz RJ, Reagan DR, Hampton KD, et al. A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann Intern Med 1996;124:539-47.
33. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91:Suppl 3B:3B-86S-3B-89S.
34. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996;23: 255-9.
35. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6: 428-42.
36. Panlilio A, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
37. Speller DCE, Johnson AP, James D, Marples RR, Charlett A, George RC. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 1997;350:323-5.
38. Moreno F, Crisp C, Jorgenscn JH, Patterson JE. Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995;21: 1308-12.
39. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
40. Sanches IS, Ramirez M, Troni H, et al. Evidence for the geographic spread of a methicillin-resistant Staphylococcus aureus clone between Portugal and Spain. J Clin Microbiol 1995;33:1243-6.
41. Dominguez MA, de Lencastre H, Linares J, Tomasz A. Spread and maintenance of a dominant methicillin-resistant Staphylococcus aureus (MRSA) clone during an outbreak of MRSA disease in a Spanish hospital. J Clin Microbiol 1994;32:2081-7.
42. Foster TJ, Hartford O, O'Donnell D. Host-pathogen protein-protein interactions in Staphylococcus. In: McCrae MA, Saunders JR, Smyth CJ, Stow ND, eds. Molecular aspects of host-pathogen interaction. Cambridge, England: Cambridge University Press, 1997:67-94.
43. Crossley KB, Archer GL, eds. The staphylococci in human disease. New York: Churchill Livingstone, 1997.
44. Sanford BA, Ramsay MA. In vivo localization of Staphylococcus aureus in nasal tissues of healthy and influenza A virus-infected ferrets. Proc Soc Exp Biol Med 1989;191:163-9.
45. Shuter J, Hatcher VB, Lowy FD. Staphylococcus aureus binding to human nasal mucin. Infect Immun 1996;64:310-8.
46. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man: a study of the problems of wound infection. Br J Exp Pathol 1957;38:573-86.
47. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection: evidence for a local granulocyte defect. J Clin Invest 1984;73: 1191-200.
48. Cheung AL, Fischetti VA. The role of fibrinogen in staphylococcal adherence to catheters in vitro. J Infect Dis 1990;161:1177-86.
49. Vaudaux P, Pittet D, Haeberli A, et al. Fibronectin is more active than fibrin or fibrinogen in promoting Staphylococcus aureus adherence to inserted intravascular catheters. J Infect Dis 1993;167:633-41.
50. Tsao MM, Katz D. Central venous catheter-induced endocarditis: human correlate of the animal experimental model of endocarditis. Rev Infect Dis 1984;6:783-90.
51. Vercellotti GM, Lussenhop D, Peterson PK, et al. Bacterial adherence to fibronectin and endothelial cells: a possible mechanism for bacterial tissue tropism. J Lab Clin Med 1984;103:34-43.
52. Ogawa SK, Yurberg ER, Hatcher VB, Levitt MA, Lowy FD. Bacterial adherence to human endothelial cells in vitro. Infect Immun 1985;50:218-24.
53. Tompkins DC, Hatcher VB, Patel D, Orr GA, Higgins LL, Lowy FD. A human endothelial cell membrane protein that binds Staphylococcus aureus in vitro. J Clin Invest 1990;85:1248-54.
54. Lowy FD, Fant J, Higgins LL, Ogawa SK, Hatcher VB. Staphylococcus aureus - human endothelial cell interactions. J Ultrastruct Mol Struct Res 1988;98:137-46.
55. Hamill RJ, Vann JM, Proctor RA. Phagocytosis of Staphylococcus aureus by cultured bovine aortic endothelial cells: model for postadherence events in endovascular infections. Infect Immun 1986;54:833-6.
56. Vesga O, Groeschcl MC, Otten MF, Brar DW, Vann JM, Proctor RA. Staphylococcus aureus small colony variants are induced by the endothelial cell intracellular milieu. J Infect Dis 1996;173:739-42.
57. Proctor RA, van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 1995;20:95-102.
58. Wu T, Yeaman MR, Bayer AS. In vitro resistance to platelet microbicidal protein correlates with endocarditis source among bacteremic staphylococcal and streptococcal isolates. Antimicrob Agents Chemother 1994; 38:729-32.
59. Alston WK, Elliott DA, Epstein ME, Hatcher VB, Tang M, Lowy FD. Extracellular matrix heparan sulfate modulates endothelial cell susceptibility to Staphylococcus aureus. J Cell Physiol 1997;173:102-9.
60. Drake TA, Pang M. Staphylococcus aureus induces tissue factor expression in cultured human cardiac valve endothelium. J Infect Dis 1988;157:749-56.
61. Ing MB, Baddour LM, Bayer AS. Bacteremia and infective endocarditis: pathogenesis, diagnosis, and complications. In: Crossley KB, Archer GL, eds. The staphylococci in human disease. New York: Churchill Livingstone, 1997:331-54.
62. Patti JM, Bremell T, Krajewska-Pietrasik D, et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun 1994;62:152-61.
63. Timmerman CP, Mattsson E, Martinez-Martinez L, et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993;61:4167-72.
64. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994;62:2715-21.
65. Yao L, Bengualid V, Lowy FD, Gibbons JJ, Hatcher VB, Berman JW. Internalization of Staphylococcus aureus by endothelial cells induces cytokine gene expression. Infect Immun 1995;63:1835-9.
66. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154:26-34.
67. Spika JS, Peterson PK, Wilkinson BJ, et al. Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia. J Infect Dis 1982;146:227-34.
68. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A 1995;92:10359-63.
69. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990;17:251-72.
70. Verdrengh M, Tarkowski A Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun 1997;65:2517-21.
71. Yao L, Berman JW, Factor SM, Lowy FD. Correlation of histopathologic and bacteriologic changes with cytokine expression in an experimental murine model of bacteremic Staphylococcus aureus infection. Infect Immun 1997;65:3889-95.
72. Beekhuizen H, van de Gevel JS, Olsson B, van Benten IJ, van Furth R. Infection of human vascular endothelial cells with Staphylococcus aureus induces hyperadhesiveness for human monocytes and granulocytes. J Immunol 1997;158:774-82.
73. Verdrengh M, Springer TA, Gutierrez-Ramos J-C, Tarkowski A. Role of intercellular adhesion molecule 1 in pathogenesis of staphylococcal arthritis and in host defense against staphylococcal bacteremia. Infect Immun 1996;64:2804-7.
74. Peterson PK, Wilkinson BJ, Kim Y, et al. The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest 1978;61:597-609.
75. Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1988;56: 1090-5.
76. Wergeland HI, Haaheim LR, Natås OB, Wesenberg F, Oeding P. Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections. J Clin Microbiol 1989;27:1286-91.
77. Freedman JD, Beer DJ. Expanding perspectives on the toxic shock syndrome. Adv Intern Med 1991;36:363-97.
78. Musher DM, Lamm N, Darouiche RO, Young EJ, Hamill RJ, London GC. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine (Baltimore) 1994;73:186-208.
79. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987;9:891-907.
80. Yzerman EPF, Boelens HAM, Tjhie JHT, Kluytmans JAJW, Mouton JW, Verbrugh HA. ΔAPACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. J Infect Dis 1996;173:914-9.
81. Sanabria TJ, Alpert JS, Goldberg R, Pape LA, Cheeseman SH. Increasing frequency of staphylococcal infective endocarditis: experience at a university hospital, 1981 through 1988. Arch Intern Med 1990;150:1305-9.
82. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984;144:541-5.
83. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993;119: 304-11.
84. Raad II, Sabbagh MF. Optimal duration of therapy of catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992;14:75-82.
85. Espersen F, Frimodt-Møller N. Staphylococcus aureus endocarditis: a review of 119 cases. Arch Intern Med 1986;146:1118-21.
86. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997;30:1072-8.
87. Sandre RM, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996;22:276-86.
88. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore) 1983;62:170-7.
89. Marantz PR, Linzer M, Feiner CJ, Feinstein SA, Kozin AM, Friedland GH. Inability to predict diagnosis in febrile intravenous drug abusers. Ann Intern Med 1987;106:823-8.
90. Pulvirenti JJ, Kerns E, Benson C, Lisowski J, Demarais P, Weinstein RA. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. J Infect Dis 1996;22:40-5.
91. Fernandez-Guerrero ML, Verdejo C, Azofra J, de Górgolas M. Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clin Infect Dis 1995;20:16-23.
92. Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia: a prospective, multicenter study. Ann Intern Med 1993;119:560-7.
93. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
94. Chesney PJ, Davis JP, Purdy WK, Wand PJ, Chesney RW. Clinical manifestations of toxic shock syndrome. JAMA 1981;246:741-8.
95. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10: 781-91.
96. Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. Trends Microbiol 1994;2: 343-7.
97. Kreiswirth B, Kornblum J, Arbeit RD, et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science 1993;259:227-30.
98. Musser JM, Kapur V. Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources: association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J Clin Microbiol 1992;30:2058-63.
99. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
100. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
101. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46: 813-5. [Erratum, MMWR Morb Mortal Wkly Rep 1997;46:851.]
102. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-66.
103. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7.
104. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
105. Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991;115:739-41.
106. Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 1997;349:1901-6.
107. Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991;114:424-6.
108. Miller MH, Wexler MA, Steigbigel NH. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother 1978;14:336-43.
109. Korzeniowski O, Sande MA, National Collaborative Study Group. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982;97:496-503.
110. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 1995;274:1706-13.
111. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug abusers with ciprofloxacin and rifampicin. Lancet 1989;2:1071-3.
112. Rahal JJ Jr, Chan Y-K, Johnson G. Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am J Med 1986;81: 43-52.
113. Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect Dis Clin North Am 1993;7:69-80.
114. Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis: a randomized, controlled trial. Ann Intern Med 1996;125:969-74.
115. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996;101:68-76.
116. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990;89:137-41.
117. Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg 1994;58:1073-7.
118. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-7.
119. Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-6.
120. Moy JA, Caldwell-Brown D, Lin AN, Pappa KA, Carter DM. Mupirocin-resistant Staphylococcus aureus after long-term treatments of patients with epidermolysis bullosa. J Am Acad Dermatol 1990;22:893-5.
121. Fattom AI, Sarwar I, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996;64:1659-65.
122. Lee JC, Park J-S, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997;65: 4146-51.
123. Balaban N, Goldkorn T, Nhan RT, et al. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science 1998; 280:438-40.
124. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:626-8, 635.
125. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329-34.